Promoting evidence-based management of anemia in cancer patients: concurrent and discriminant validity of RESPOND, a web-based clinical guidance system based on the EORTC guidelines for supportive care in cancer

Goal of workThe goal of this study is to test the validity of RESPOND, a web-based decision support system to assess and manage anemia in cancer patients as per the European Organisation for Research and Treatment of Cancer (EORTC) guidelines. The intraclass correlation metrics for the algorithmic definitions were reported previously. Reported here are the concurrent validity, the extent to which clinicians' anemia management is guidelines-congruent when using the system; and discriminant validity, the extent to which clinicians practice in congruence with guidelines when vs. when not using the system.Patients and methodsHybrid matched design with precohort (retrospective; clinicians not using RESPOND) and postcohort (prospective; clinicians using RESPOND) of anemic patients matched on cancer type and chemotherapy regimen and followed up over 4 months after treatment initiation with erythropoietic proteins (34 patients per cohort; total N = 68). Congruence scores quantified the extent to which anemia management was congruent with the EORTC guidelines (range 0–10).Main resultsHemoglobin (Hb) increased significantly for both cohorts, but the postcohort group showed more rapid rate of Hb increase over time (p < 0.006), higher Hb by visit 4 (p = 0.007), and greater Hb increase by visit 4 (p = 0.006). Concurrent validity was high with mean postcohort congruence scores of 8.18 ± 1.38. Discriminant validity was inferred from statistically significant differences in mean congruence scores between cohorts (p < 0.001) and from the postcohort having odds ratios of 3.64 for patients to reach Hb ≥ 11 g/dL and 2.91 to achieve Hb ≥ 12 g/dL.ConclusionsRESPOND, a validated computerized clinical guidance system with an incremental effect beyond the pharmacotherapeutic effect of erythropoietic proteins, offers clinicians accurate and safe guidance in managing anemia in cancer patients.

[1]  C. Bokemeyer,et al.  Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision support system for supportive cancer care , 2007, Supportive Care in Cancer.

[2]  Allen R Nissenson,et al.  Anemia: not just an innocent bystander? , 2003, Archives of internal medicine.

[3]  M. Aapro,et al.  Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: initial evidence from the RESPOND study. , 2009, European journal of cancer.

[4]  C. Bokemeyer,et al.  EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. , 2004, European journal of cancer.

[5]  Dirk Schrijvers,et al.  The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. , 2004, European journal of cancer.

[6]  M. Somerfield,et al.  Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. , 2008, Blood.

[7]  M. Aapro,et al.  Promoting evidence-based management of anemia in cancer patients: background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines. , 2008, Critical reviews in oncology/hematology.

[8]  V. Goel,et al.  Compliance with practice guidelines for node-negative breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Eddy.  Evidence-based medicine: a unified approach. , 2005, Health affairs.

[10]  Benjamin Djulbegovic,et al.  Quality and methods of developing practice guidelines , 2002, BMC Health Services Research.

[11]  E. Balas,et al.  Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success , 2005, BMJ : British Medical Journal.

[12]  C. Bokemeyer,et al.  Erythropoietins should be used according to guidelines. , 2008, The Lancet. Oncology.

[13]  D. Cella,et al.  Factors influencing quality of life in cancer patients: anemia and fatigue. , 1998, Seminars in oncology.

[14]  P. Johnston,et al.  Cancer-Related Anemia: Biological Findings, Clinical Implications and Impact on Quality of Life , 2005, Oncology.

[15]  M. Aapro,et al.  September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. , 2008, The oncologist.

[16]  Lawrence M. Fagan,et al.  Medical informatics: computer applications in health care and biomedicine (Health informatics) , 2003 .

[17]  F. Chauvin,et al.  Economic impact of harmonizing medical practices: compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Rivard,et al.  Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Watine,et al.  Anemia as an independent prognostic factor for survival in patients with cancer , 2002, Cancer.

[20]  C. Bokemeyer,et al.  EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. , 2007, European journal of cancer.

[21]  M. Tonelli,et al.  Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis , 2009, Canadian Medical Association Journal.

[22]  E. Shortliffe.  Clinical decision-support systems , 1990 .

[23]  T. Wilt,et al.  A meta-analysis of randomised trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: are these data relevant to modern practice? , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

[24]  David W. Bates,et al.  Synthesis of Research Paper: Ten Commandments for Effective Clinical Decision Support: Making the Practice of Evidence-based Medicine a Reality , 2003, J. Am. Medical Informatics Assoc..

[25]  J. Groopman,et al.  Chemotherapy-induced anemia in adults: incidence and treatment. , 1999, Journal of the National Cancer Institute.

[26]  Erythropoietin analogues: an unnecessary class of drugs. , 2008, The Lancet. Oncology.

[27]  S. Woolf,et al.  Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. , 2002, Blood.

[28]  B. Hillner,et al.  Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Cross,et al.  Antibody negative coeliac disease presenting in elderly people—an easily missed diagnosis , 2005, BMJ : British Medical Journal.

[30]  M. Zwahlen,et al.  Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials , 2009, The Lancet.

[31]  L. Hayden,et al.  Ten Commandments for Effective Clinical Decision Support: Making the Practice of Evidence-based Medicine a Reality , 2011 .

[32]  F. Khuri.  Weighing the hazards of erythropoiesis stimulation in patients with cancer. , 2007, The New England journal of medicine.

[33]  S. Timmermans,et al.  The promises and pitfalls of evidence-based medicine. , 2005, Health affairs.

[34]  C. Bokemeyer,et al.  Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. , 2009, European journal of cancer.